BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26140849)

  • 1. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
    Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiomics analysis of pre-treatment [
    van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Texture analysis of high-resolution dedicated breast
    Moscoso A; Ruibal Á; Domínguez-Prado I; Fernández-Ferreiro A; Herranz M; Albaina L; Argibay S; Silva-Rodríguez J; Pardo-Montero J; Aguiar P
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):196-206. PubMed ID: 28936601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with
    Lemarignier C; Martineau A; Teixeira L; Vercellino L; Espié M; Merlet P; Groheux D
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1145-1154. PubMed ID: 28188325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Tumor Burden Assessed by Dual Time Point [
    Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
    Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?
    Evangelista L; Cervino AR; Ghiotto C; Saibene T; Michieletto S; Fernando B; Orvieto E; Guarneri V; Conte P
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1648-1655. PubMed ID: 26025244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of biological and clinical aggressiveness of invasive ductal breast cancer using baseline 18F-FDG PET/CT-derived volumetric parameters.
    Ege Aktas G; Taştekin E; Sarikaya A
    Nucl Med Commun; 2018 Jan; 39(1):83-93. PubMed ID: 29135722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.
    Kajáry K; Tőkés T; Dank M; Kulka J; Szakáll S; Lengyel Z
    Nucl Med Commun; 2015 Jan; 36(1):28-37. PubMed ID: 25299471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma.
    Cheng NM; Fang YH; Chang JT; Huang CG; Tsan DL; Ng SH; Wang HM; Lin CY; Liao CT; Yen TC
    J Nucl Med; 2013 Oct; 54(10):1703-9. PubMed ID: 24042030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma.
    Hyun SH; Kim HS; Choi SH; Choi DW; Lee JK; Lee KH; Park JO; Lee KH; Kim BT; Choi JY
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1461-8. PubMed ID: 26872788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The relationship between (18)F-FDG PET/CT metabolic parameters and clinicopathological features of breast cancer].
    Tang B; Zhang Y; Zhou J; Xu Y; Li TR; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):280-285. PubMed ID: 28550668
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
    Tixier F; Vriens D; Cheze-Le Rest C; Hatt M; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP; Visvikis D
    J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability of
    Jena A; Taneja S; Singh A; Negi P; Sarin R; Das PK; Singhal M
    AJR Am J Roentgenol; 2017 Sep; 209(3):662-670. PubMed ID: 28678576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer.
    Garcia-Vicente AM; Molina D; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Bueno G; Tello-Galán MJ; Soriano-Castrejón Á
    Ann Nucl Med; 2017 Dec; 31(10):726-735. PubMed ID: 28887761
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Lasnon C; Majdoub M; Lavigne B; Do P; Madelaine J; Visvikis D; Hatt M; Aide N
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2324-2335. PubMed ID: 27325312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT.
    Nakajo M; Nakajo M; Jinguji M; Fukukura Y; Nakabeppu Y; Tani A; Yoshiura T
    Br J Radiol; 2015; 88(1055):20150552. PubMed ID: 26337605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.